Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06616870

Study of the Predictive and Prognostic Role of Pharmacogenetic and Radiogenic Variants on the Response to Neoadjuvant Chemoradiation Therapy in Patients With Locally Advanced Rectal Cancer

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
460 (estimated)
Sponsor
Centro di Riferimento Oncologico - Aviano · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

In locally advanced rectal cancer the pathological complete response (pCR) to neoadjuvant chemoradiation therapy (nCRT) is associated with a favourable long-term prognosis. The identification of markers predictive of response to therapy would therefore optimise treatment by allowing personalised therapy. It has been shown that the genetic profile of the patient could influence the activation of the immune system in combination with chemoradiation therapy in targeting tumour cells. In addition, genetic features of molecular pathways correlated with response to chemoradiotherapy, may in turn affect the probability of a good response to treatment in these patients, but also the occurrence of adverse events. The main objective of the study is to define the role of genetic markers related to immune system activation and other molecular pathways in predicting the complete pathological response to preoperative chemoradiation therapy in patients with locally advanced rectal cancer.

Conditions

Timeline

Start date
2024-10-03
Primary completion
2029-10-03
Completion
2029-10-03
First posted
2024-09-27
Last updated
2024-09-27

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT06616870. Inclusion in this directory is not an endorsement.